- Penumbra reported third quarter 2026 results with sales of US$410.15 million and net income of US$42.28 million, alongside updated nine month figures.
- The mix of higher sales and lower earnings per share hints at cost or margin pressures that matter for how Penumbra’s business is being run.
- We will look at how Penumbra's investment narrative compares with this mix of higher quarterly sales and softer profitability.
Compare Penumbra’s mix of stronger sales and softer earnings with peers by scanning our hand-picked 42 high quality undervalued stocks, which pair solid cash generation with balance sheets built for pressure like this.
Penumbra Investment Narrative Recap
To own Penumbra, you need to be comfortable with a story where thrombectomy and embolization continue to build scale while management works to defend margins. The latest quarter fits that tension. Sales reached US$410.15 million, yet net income slipped to US$42.28 million and earnings per share were lower, which keeps cost discipline in the spotlight.
The short term swing factor is still execution on higher margin product mix and manufacturing efficiency, especially with prior quarters already showing pressure on net profit margins. The biggest risk is that rising expenses, deal related items, or integration work linked to Boston Scientific keep chipping away at earnings power even when top line performance is solid.
The most relevant update here is the same third quarter and nine month earnings release on October 29, 2026, because it refreshes the scorecard on that margin story. Over the first nine months of 2026, Penumbra reported sales of US$1,174.95 million and net income of US$109.67 million. This gives you a cleaner read on year to date profitability than a single quarter.
Those figures sit against analysts’ earlier expectations for earnings expansion and help you judge execution against the margin and growth catalysts already in play, such as thrombectomy adoption and embolization scale up. For anyone tracking the Boston Scientific deal and cost structure, the combination of higher revenue and softer earnings per share keeps the spotlight firmly on operating leverage and integration risk.
Penumbra's narrative projects US$2.1b revenue and US$296.3 million earnings by 2029. This assumes 12.1% yearly revenue growth and an earnings increase of about US$135.7 million from US$160.6 million today.
Uncover how Penumbra's fair value indicates a 13% potential upside to its current price that could narrow quickly.
Exploring Other Perspectives
The lowest analysts focus less on Penumbra’s thrombectomy upside and more on merger risk with Boston Scientific. They were working off earnings forecasts of about US$291.4 million by 2029 on roughly US$2.1b of revenue, and a 55.7x P/E. That is a cooler story. Today’s earnings update may eventually shift those expectations.
Explore another Penumbra fair value estimate, including one that suggests as much as 28% downside from the current price.
Form Your Own Verdict
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
- A great starting point for your Penumbra research is our analysis highlighting 1 key reward that could impact your investment decision.
- See our latest analysis for Penumbra. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Penumbra's overall financial health at a glance.
Looking for more investment ideas beyond Penumbra?
Penumbra may be your starting point, but real diversification comes from lining up a few different types of opportunities and comparing the trade offs side by side. The Simply Wall St Screener can help you move from a single stock story to a watchlist that genuinely fits your goals.
- If you want potential growth with strict quality filters, scan a curated set of smaller companies through 21 high quality undiscovered gems that already show strong underlying fundamentals.
- If resilience matters most to you, focus on a list of solid balance sheet and fundamentals (24 results) that can better handle earnings bumps and tougher financing conditions.
- If capital preservation and smoother returns are higher on your list, start with 32 resilient stocks with low risk scores that score well on Simply Wall St's risk metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com